Open AccessAngiopoietins as Potential Targets in Management of Retinal Disease
Author(s) -
Arshad M. Khanani,
Matthew W. Russell,
Aamir Aziz,
Carl J Danzig,
Christina Y. Weng,
David Eichenbaum,
Rishi P. Singh
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s231801
Subject(s) - medicine , retinal , ophthalmology , clinical trial , vegf receptors , bevacizumab , vascular endothelial growth factor , pharmacology , chemotherapy
The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases such as DME, AMD, and RVO by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials. Recent Year 1 data from phase III clinical trials YOSEMITE, RHINE, TENAYA, and LUCERNE have confirmed the efficacy, safety, durability, and superiority of faricimab in patients with DME and nAMD. Faricimab, if approved, may significantly decrease treatment burden in patients with retinal vascular diseases to a greater extent than would current standard of care anti-VEGF injections.